TIRCON: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)

Trial Profile

TIRCON: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Pantothenate kinase-associated neurodegeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms TIRCON
  • Sponsors ApoPharma
  • Most Recent Events

    • 22 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 19 Nov 2016 This trial has been completed in Germany (end date:2016-10-21), according to European Clinical Trials Database record.
    • 30 Mar 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top